FY2024 Earnings Estimate for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company will post earnings per share of ($0.41) for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at $0.14 EPS.

Other analysts have also recently issued reports about the stock. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Oppenheimer raised their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. StockNews.com lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH boosted their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Stock Up 3.4 %

Shares of CRVS stock opened at $6.03 on Monday. The company’s 50 day moving average is $7.62 and its 200 day moving average is $5.36. The firm has a market cap of $387.47 million, a price-to-earnings ratio of -6.48 and a beta of 1.07. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of Corvus Pharmaceuticals by 441.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company’s stock valued at $262,000 after acquiring an additional 40,404 shares during the last quarter. Virtu Financial LLC purchased a new stake in Corvus Pharmaceuticals in the third quarter valued at $83,000. Geode Capital Management LLC grew its position in Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after purchasing an additional 102,869 shares during the period. XTX Topco Ltd acquired a new stake in Corvus Pharmaceuticals during the 3rd quarter worth about $74,000. Finally, Jane Street Group LLC purchased a new position in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $265,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.